問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Far Eastern Memorial Hospital (在職)

Division of Nephrology

Division of Endocrinology

更新時間：2023-09-19

邱彥霖
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

24Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱彥霖

List

37Cases

2017-01-01 - 2018-12-31

Phase IV

A Long-Term, Open-Label, Prospective Observational Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects with End Stage Renal Disease (ESRD) on Dialysis.

  • Condition/Disease

    Hyperphosphatemia/End Stage Renal Disease (ESRD)

  • Test Drug

    NEPHOXIL®

Participate Sites
9Sites

Terminated9Sites

2015-01-01 - 2017-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis

  • Condition/Disease

    Chronic Kidney Disease

  • Test Drug

    Roxadustat

Participate Sites
12Sites

Study ended12Sites

洪振傑
Linkou Chang Gung Medical Foundation

Division of Nephrology

唐德成
Taipei Veterans General Hospital

Division of Nephrology

2015-01-01 - 2020-06-30

Phase III

A phase 3 multicenter, prospective, randomized, double-blind, placebo controlled study to investigate the safety and efficacy of ZS (sodium zirconium cyclosilicate), in patients with hyperkalemia - HARMONIZE Global

  • Condition/Disease

    Hyperkalemia

  • Test Drug

    ZS

Participate Sites
7Sites

Terminated7Sites

2016-12-01 - 2021-11-30

Phase III

A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa

  • Condition/Disease

    non-dialysis with anemia associated with chronic kidney disease

  • Test Drug

    Daprodustat (GSK1278863)

Participate Sites
12Sites

Recruiting7Sites

Terminated5Sites

蘇裕謀
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Nephrology

2016-12-01 - 2020-12-31

Phase III

ASCEND-D: A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents

  • Condition/Disease

    dialysis subjects with anemia associated with chronic kidney disease

  • Test Drug

    Daprodustat (GSK1278863)

Participate Sites
12Sites

Terminated12Sites

2021-11-01 - 2026-02-28

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

2015-11-16 - 2022-01-31

Phase III

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care

  • Condition/Disease

    Diabetic kidney disease

  • Test Drug

    BAY 94-8862/ Finerenone

Participate Sites
9Sites

Terminated9Sites

吳麥斯
Taipei Medical University Hospital

Division of Nephrology

唐德成
Taipei Veterans General Hospital

Division of Nephrology

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB